Cypress Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Cypress Capital’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$268K	Hold	6,000	–	–	0.07%	96
2026 Q2	$476K	Hold	6,000	–	–	0.13%	74
2026 Q1	$451K	Sell	6,000 -4,000	-40%	-$316K	0.13%	69
2025 Q4	$791K	Hold	10,000	–	–	0.22%	56
2025 Q3	$654K	Hold	10,000	–	–	0.19%	60
2025 Q2	$395K	Hold	10,000	–	–	0.11%	68
2025 Q1	$302K	Hold	10,000	–	–	0.09%	69
2024 Q4	$350K	Hold	10,000	–	–	0.1%	65
2024 Q3	$401K	Hold	10,000	–	–	0.1%	67
2024 Q2	$477K	Hold	10,000	–	–	0.12%	67
2024 Q1	$434K	Buy	+10,000	New	+$477K	0.12%	63
2021 Q2	–	Sell	-25	Closed	-$1K	–	95
2021 Q1	$1K	Buy	+25	New	+$1.39K	﹤0.01%	101

Other funds holding IONS

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Nicollet Investment Management Minneapolis, Minnesota $336M AUM 22.24% 1-Year Est. Return

Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Frank Rimerman Advisors Palo Alto, California $1.81B AUM 32.96% 1-Year Est. Return

Avior Wealth Management Omaha, Nebraska $3.79B AUM 15.36% 1-Year Est. Return

Cypress Capital's IONS Position: Q3 2026 in Review

Cypress Capital held its Ionis Pharmaceuticals (IONS) position steady in Q3 2026 at 6,000 shares worth $268K. The position accounts for 0.07% of the portfolio, ranked #96.

Cypress Capital first reported a position in IONS in Q1 2021 and has held it in 12 quarters since. The position peaked at $791K in Q4 2025. 46 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

Cypress Capital held 6,000 shares of Ionis Pharmaceuticals worth $268K as of Q3 2026.
Cypress Capital left its Ionis Pharmaceuticals share count unchanged in Q3 2026.
Ionis Pharmaceuticals made up 0.07% of Cypress Capital's portfolio in Q3 2026, its #96 holding.
Cypress Capital first reported a position in Ionis Pharmaceuticals in Q1 2021 and has held it in 12 quarters since.
Cypress Capital's Ionis Pharmaceuticals position peaked at $791K in Q4 2025.
46 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on Cypress Capital's 13F filing for Q3 2026, filed 20 Oct 2026.